Clinical trials: Locally Advanced Colorectal Cancer
Colon Cancer (Stage II &Amp;Amp; III)
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
In patients with high-risk stage II and stage III colon cancer, curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become the standard treatment.
- Trial name
- OPTICAL-3 (NCT06890624)
- Testing
- cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
This phase II trial investigates the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04751370
- Testing
- Computed Tomography, Ipilimumab, Magnetic Resonance Imaging
- Where
- 213 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Colonic Neoplasms
Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer
In the current treatment of colon cancer, the definition of locally advanced colon cancer (LACC) is controversial, and the clinical trial evidence which support treatment for LACC is not clear.
- Trial name
- NCT01826396
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences
Colorectal Carcinoma
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal cancer staged as locally advanced…
- Trial name
- NCT04833387
- Testing
- PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Rectal Neoplasms
Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Standard care for locally advanced rectal cancer consists in a neoadjuvant therapy followed by surgery. Morbidity and mortality remain high after rectal surgery, and often linked with quality of life impairment.
- Trial name
- NCT05534841
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Rectal Carcinoma
Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma
the study will discuss different pattern of treatment and the outcomes of locally advanced rectal carcinoma as a retrospective study.
- Trial name
- NCT07363863
- Testing
- No Intervention (subjects were previously treated with Onglyza®)
- Volunteers
- 100 people
- Sponsor
- Sohag University
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.
- Trial name
- NCT06024356
- Testing
- Thymalfasin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Beijing Friendship Hospital
Rectal Neoplasms
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
The purpose of this study is to determine whether 18F-FDG-PET-CT and texture analysis of MRI performed 9 weeks after Neoadjuvant Chemo-radiotherapy in patients with locally advanced rectal cancer has the ability to identify…
- Trial name
- PRENT-LARC (NCT02439086)
- Testing
- PET-CT Scan
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Colchester General Hospital
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Rectal Cancer
No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer
This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by…
- Trial name
- NOAHS-ARC (NCT04864067)
- Testing
- Oxaliplatin, 5-Fluoracil, Leucovorin
- Where
- 3 sites in Chile
- Volunteers
- 39 people
- Sponsor
- Servicio de Salud Metropolitano Sur Oriente
Rectal Cancer
Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
This study includes patients affected by advanced and resectable rectal adenocarcinoma. It provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by Chemoradiotherapy plus Bevacizumab.
- Trial name
- TRUST (NCT03085992)
- Testing
- FOLFOXIRI plus Bevacizumab, Chemoradiotherapy plus Bevacizumab
- Where
- 4 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer
Title:A Single-Arm, Single-Center, Phase II Exploratory Study of Serplulimab Combined with Decitabine plus CAPOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Background:Colorectal cancer is one of the most common…
- Trial name
- NCT07691632
- Testing
- Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Rectal Cancer, Rectal Cancer Stage II
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced MSS rectal cancer.
- Conditions
- Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT06254521
- Testing
- Tislelizumab combined with chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Rectal Cancer
Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy
This trial is to assess the efficacy and feasibility of consolidation chemotherapy after neoadjuvant chemoradiotherapy for locally advanced mid or low rectal cancer.
- Trial name
- NCT02843191
- Testing
- Chemotherapy
- Where
- 14 sites in South Korea
- Volunteers
- 358 people
- Sponsor
- Kyung Hee University Hospital at Gangdong
Rectal Cancer
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
This trial examines the feasibility, effectiveness and safety of a combination of radiotherapy (over a period of five weeks) and chemotherapy (with 5-FU or Capecitabine and Oxaliplatin) and 10 fractions of deep regional…
- Trial name
- HyRec (NCT01716949)
- Testing
- Radiotherapy, Hyperthermia, 5-Fluorouracil
- Where
- 6 sites in Germany
- Volunteers
- 59 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Colorectal Cancer
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.
- Trial name
- NCT00469443
- Testing
- Irinotecan, 5-Fluorouracil, Leucovorin
- Where
- 8 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Oncology Research Group